scholarly journals Kidney Transplant Recipients with Cutaneous Squamous Cell Carcinoma Have an Increased Risk of Internal Malignancy

2012 ◽  
Vol 132 (9) ◽  
pp. 2176-2183 ◽  
Author(s):  
Hermina C. Wisgerhof ◽  
Ron Wolterbeek ◽  
Johan W. de Fijter ◽  
Rein Willemze ◽  
Jan N. Bouwes Bavinck
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Kidney Transplant ◽  
Squamous Cell ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Internal Malignancy ◽  
Increased Risk

scholarly journals Increased Risk of Squamous-Cell Carcinoma in Simultaneous Pancreas Kidney Transplant Recipients Compared with Kidney Transplant Recipients

2009 ◽  
Vol 129 (12) ◽  
pp. 2886-2894 ◽  
Author(s):  
Hermina C. Wisgerhof ◽  
Paul J.M. van der Boog ◽  
Johan W. de Fijter ◽  
Ron Wolterbeek ◽  
Geert W. Haasnoot ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Kidney Transplant ◽  
Squamous Cell ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Increased Risk ◽  
Simultaneous Pancreas Kidney

Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results

2018 ◽  
Vol 36 (25) ◽  
pp. 2612-2620 ◽  
Author(s):  
Jacques Dantal ◽  
Emmanuel Morelon ◽  
Lionel Rostaing ◽  
Eric Goffin ◽  
Anabelle Brocard ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Kidney Transplant ◽  
Squamous Cell ◽  
Calcineurin Inhibitor ◽  
Calcineurin Inhibitors ◽  
Squamous Cell Carcinomas ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Skin Cancers

Purpose Transplant recipients who develop cutaneous squamous cell carcinomas are at high risk for multiple subsequent skin cancers. Sirolimus has been shown to reduce the occurrence of secondary skin cancers, but no study included a follow-up exceeding 2 years. We extended at 5 years the TUMORAPA randomized trial of sirolimus-based immunosuppressive regimen versus calcineurin inhibitor–based immunosuppression. Methods Kidney transplant recipients receiving calcineurin inhibitors who had at least one cutaneous squamous cell carcinoma were randomly assigned to receive sirolimus as a substitute for calcineurin inhibitors (n = 64) or to maintain their initial treatment (n = 56). The primary end point was survival free of squamous cell carcinoma at 5 years. Secondary end points included the occurrence of other skin cancers, renal function, patient and graft survival, and treatment tolerance. Results Survival free of cutaneous squamous cell carcinoma was significantly longer in the sirolimus group than in the calcineurin inhibitor group ( P = .007). In the sirolimus group, the number of patients with new skin cancers was significantly lower compared with the calcineurin inhibitor group: 22% versus 59% for squamous cell carcinomas ( P < .001), 34% versus 66% for other skin cancers ( P < .001), and 20% versus 37.5% for basal cell carcinomas ( P < .05). Kidney graft function, patients, and graft survival were similar in both groups. In the sirolimus group, the mean number of serious adverse effects per patient decreased from 1.16 during the first 2 years, to 0.83 between years 2 and 5. Conclusion In kidney transplant recipients with previous cutaneous squamous cell carcinomas, the antitumoral effect of conversion from calcineurin inhibitors to sirolimus was maintained at 5 years, and sirolimus tolerance was satisfactory.

De-Methylation of the TSDR Is a Marker of Squamous Cell Carcinoma in Kidney Transplant Recipients.

2014 ◽  
Vol 98 ◽  
pp. 321
Author(s):  
S. Sherston ◽  
K. Vogt ◽  
S. Schlickeiser ◽  
B. Sawitzki ◽  
P. Harden ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Kidney Transplant ◽  
Squamous Cell ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals Association between Use of Hydrochlorothiazide and Risk of Keratinocyte Cancers in Kidney Transplant Recipients

2020 ◽  
Vol 15 (12) ◽  
pp. 1804-1813
Author(s):  
Thibault Letellier ◽  
Florent Leborgne ◽  
Clarisse Kerleau ◽  
Aurélie Gaultier ◽  
Jacques Dantal ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Kidney Transplant ◽  
Squamous Cell ◽  
Basal Cell ◽  
Squamous Cell Carcinomas ◽  
Transplant Recipients ◽  
Single Center ◽  
Kidney Transplant Recipients ◽  
Basal Cell Carcinomas ◽  
Keratinocyte Cancer

Background and objectivesKeratinocyte cancers, which primarily comprise squamous cell carcinomas and basal cell carcinomas, represent a major concern and potential risk for kidney transplant recipients. Hydrochlorothiazide, a diuretic widely used to treat hypertension, has been implicated in skin photosensitivity reaction. Recent studies conducted in the general population have found that hydrochlorothiazide use is associated with a higher risk of keratinocyte cancer, especially squamous cell carcinomas. High-risk groups, however, including transplant recipients were excluded from these. Our aim was to investigate whether hydrochlorothiazide use was associated with keratinocyte cancer in kidney transplant recipients on immunosuppressive therapy.Design, setting, participants, & measurementsIn a single-center cohort of kidney (n=2155), combined kidney-pancreas (n=282), and pancreas (n=59) transplant recipients from the Données Informatisées VAlidées Transplantation (DIVAT) database transplanted between 2000 and 2017 in Nantes, France, we evaluated the association between hydrochlorothiazide exposure and keratinocyte cancers. Multivariable cause-specific, time-varying Cox models were used to estimate the relationship between hydrochlorothiazide exposure and the hazard of squamous cell carcinoma and basal cell carcinoma, with hydrochlorothiazide designated as the time-dependent variable.ResultsAmong the participants, 279 of 2496 (11%) were exposed to hydrochlorothiazide after the transplantation. Cumulative incidence rates of keratinocyte cancer by 10 and 15 years were 7% and 9% for squamous cell carcinomas, respectively, and 8% and 11% for basal cell carcinomas, respectively. We found a relationship between exposure to hydrochlorothiazide and the risk of squamous cell carcinomas (hazard ratio, 2.04; 95% confidence interval, 1.27 to 3.28). In contrast, we found no association between hydrochlorothiazide exposure and basal cell carcinomas (hazard ratio, 0.63; 95% confidence interval, 0.35 to 1.15).ConclusionsIn a single-center cohort of kidney, combined kidney-pancreas, and pancreas transplant recipients, exposure to hydrochlorothiazide was associated with a two-fold higher risk of squamous cell carcinoma and no higher risk of basal cell carcinoma.

Sign in / Sign up

Export Citation Format

Share Document